Uganda is poised to adopt Lenacapavir, a groundbreaking HIV prevention method, following promising results from Gilead Sciences’ PURPOSE 1 trial. The trial, conducted in Uganda and South Africa, demonstrated 100% effectiveness in preventing HIV transmission among women and adolescent girls.…

Lenacapavir, which is administered twice yearly, was subjected to a phase three trial in which 5,300 girls and young women aged 16-25 in Uganda and South Africa participated Read more >>>>>>>>>>>>>>>

After over a decade of working on HIV PrEP trials, it’s extremely fulfilling to get such amazing results from the PURPOSE1 study,” said Dr Flavia Matovu Kiweewa. Read more >>>>>>

The Health Ministry has announced the administration of the first dose of the HIV prevention drug Cabotegravir (Cab-LA) as part of the country’s rollout of long-acting HIV prevention options.  Read more >>>>

Twice-Yearly Lenacapavir or Daily Oral Emtricitabine/Tenofovir Alafenamide for HIV Prevention in Cisgender Women: Interim Analysis Results from the PURPOSE 1 Study Read more >>>>https://www.busogahealthforum.org/download/purpose-1-study-first-phase-3-hiv-prevention-trail-to-show-zero-infections/?wpdmdl=2889&refresh=67307eb1d4b1c1731231409